BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 5, 2026
Home » Blogs » BioWorld Perspectives » The Star-Struck FTC

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

The Star-Struck FTC

July 2, 2012
By Mari Serebrov

The FTC seems to have come down with a bad case of star envy. Not content with its supporting role as implementer of laws duly passed by Congress, the agency is intent on rewriting the script, casting itself as headliner hero, executive producer, star-making director and congratulatory movie critic.

(Bring up music intro.)

In its colorized remake of the budget-busting melodrama How Government Functions, the FTC plays the white-hatted good guy come to cut down the gang of biopharma villains while the local sheriff (Congress) sits idly by, his pockets stuffed with Big Pharma bribes. The action climaxes as the FTC rescues the sweet, helpless heroine, Ms. Generics, and speeds her on her way to the marketplace. As the sun sets, the townspeople, long beholden to the greed of the biopharma gang, cheer loudly and stock their medicine cabinets with nothing but generic drugs.

(Clapping FX as the FTC flashes its applause light. Fade to black.)

Rather than rewriting its lines, the FTC needs to stick to the script, and role, it’s been handed. Like it or not, Congress is the elected star of the Beltway – and the only writer of federal laws.

If Congress wants to end pay-for-delay settlements, it can pass a law to do it. It thought about it while scripting PDUFA. But it decided not to.

If Congress wants to close the loophole that permits brand companies to restrict generics’ access to drugs with risk evaluation and mitigation strategies, it can pass a law to do it. Lawmakers also thought about that while fleshing out PDUFA. But, again, they decided not to.

The FTC needs to stop trying to steal the show by ad-libbing laws as it goes along. As an appointed commission, it doesn’t have the chops to be the lawmaker. Or even the understudy.

(Roll credits. Be sure that “FTC” comes after the name of the stars and is in smaller print as is befitting the role of supporting actors.)

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • Black wavy lines forming an abstract sound wave.png

    Deep brain stimulation from the shallows: tomorrow’s BCI technology?

    BioWorld
    Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
  • AI-generated image for brain organoid neural research

    CINP 2026: organoids reveal autism and addiction mechanisms

    BioWorld Science
    At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

    BioWorld Science
    Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing